Research
Hormonal
Menopause increases total body fat mass and decreases fat-free mass, leading to a shift toward visceral adiposity, without significantly changing total body weight or BMI.
Do not rely on body weight or BMI to track health during menopause. Expect a shift in body composition: you will likely gain fat (especially visceral) and lose muscle. Prioritize resistance training to preserve lean mass and manage visceral fat, as total weight may remain stable while health risks increase.
GoodSupportsHIGH confidence
Strikingly, these studies indicate that in both healthy-weight and mildly obese women, menopause increases body fat by ~5% of body weight and decreases fat-free body mass by a slightly smaller amount. These opposing changes explain why menopause has no marked effect on body weight or BMI in most studies.
Why this rating
Based on multiple cross-sectional studies using DEXA and MRI, segregated from aging effects.
Source
Ovarian hormones and obesity
Brigitte Leeners et al. · Human Reproduction Update · 2016
DOI 10.1093/humupd/dmw045
systematic_reviewCited 402×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Estrogen levels are inversely associated with adiposity in premenopausal women, with higher estradiol levels found in healthy-weight women compared to obese women, suggesting a role for estrogens in restraining adipose tissue accumulation.Good
- Estrogen hormone therapy in postmenopausal women reduces fat mass and improves body composition without significantly changing total body weight or BMI.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →